Keywords
How to Cite
Abstract
This article aims to conduct a systematic review and meta-analysis to compare the efficacy and safety of bempedoic acid to statins in the treatment of dyslipidemia. The methodology followed PRISMA guidelines, utilizing the PubMed, Embase, Cochrane Library, and Scopus databases with the terms "bempedoic acid," "statins," "cardiovascular events," "mortality," and "adverse events." Randomized clinical trials published up to January 1, 2025, were included. The results showed that bempedoic acid did not demonstrate superiority over statins in reducing cardiovascular events and mortality but did show a lower occurrence of adverse events. It is concluded that bempedoic acid is a viable alternative for statin-intolerant patients, but further studies are needed to clarify its impact on cardiovascular risk reduction.
References
DI MINNO, Alessandro; LUPOLI, Roberta; CALCATERRA, Ilaria; et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association, v. 9, n. 12, p. e016262, 2020. Disponível em: REVISTAS AHA. Acesso em: 22 jan. 2025.
MUTSCHLECHNER, David; TSCHARRE, Manuela; HUBER, Kurt; GREMMEL, Thomas. Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, v. 9, n. 6, p. 583–591, 2023.
KRISHNA MOHAN, G. V.; CHENNA, V. S. H.; TIRUMANDYAM, G.; et al. Efficacy and safety of bempedoic acid to prevent cardiovascular events in individuals at risk of cardiovascular diseases: a meta-analysis of randomized-control trials. Cureus, v. 15, n. 5, p. e38662, 2023.
BALLANTYNE, Christie M.; BANACH, Maciej; CATAPANO, Alberico L.; et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. Journal of the American College of Cardiology, v. 78, n. 2, p. 115–129, 2021.
GITTOES, Neil J. L.; SCHEEN, André J.; PETERSEN, John; et al. A randomized, double-blind, placebo-controlled, phase 3 trial of bempedoic acid in patients with hypercholesterolemia and statin intolerance. European Journal of Preventive Cardiology, v. 28, n. 10, p. 1052–1060, 2021.
THOMPSON, Paul D.; RUBINO, John; STERLING, Lulu R.; et al. Bempedoic acid in patients with statin intolerance: pooled analysis of phase 3 trials. Journal of Clinical Lipidology, v. 14, n. 5, p. 678–687, 2020.
GINSBERG, Henry N.; RITCHIE, Mary; GUPTA, Anuradha; et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis, v. 277, p. 195–203, 2018.
BALLANTYNE, Christie M.; DAVIDSON, Michael H.; MACDOUGALL, Diane E.; et al. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis, v. 277, p. 195–203, 2018.
RAY, Kausik K.; LANDMESSER, Ulf; LEITER, Lawrence A.; et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. New England Journal of Medicine, v. 376, p. 1430–1440, 2017.
CANNON, Christopher P.; BLAZING, Michael A.; GIUGLIANO, Robert P.; et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine, v. 372, p. 2387–2397, 2015.
SABATINE, Marc S.; GIUGLIANO, Robert P.; KEECH, Anthony C.; et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, v. 376, p. 1713–1722, 2017.
SCHWARTZ, Gerald G.; STEG, Philippe G.; SZAREK, Michael; et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine, v. 379, p. 2097–2107, 2018.
FERGUSON, John F.; BERGLUND, Lars; CARR, John J.; et al. Genetic variation in the β2-adrenergic receptor is associated with carotid intima-media thickness in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, v. 233, n. 2, p. 661–668, 2014.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Matheus Jannuzzi Moreira de Mendonça, Vitor Aliot da Costa, Vitor Hugo Becchi Rubio, Paulo Rogério Borges Rosmaninho Varandas, Ana Carolina Furio da Cunha, Valter Zumpano Filho, Higor Rafael de Figueiredo Oliveira